Table 8.

Patient value conferred by drug classes across medicine [16, 37]

Drug class	Indication	# of drugs	Patient value gain (%)
Histamine H-1 receptor antagonists, oral	Seasonal allergy	10	4–7
Histamine H-1 receptor antagonists, topical ocular	Allergy, ocular	6	0.1–9.9
SSRI drugs	Depression, major	5	20–23
Anti-depressants, non-SSRI	Depression, major	6	21–32
cGMP-specific phosphodi-esterase inhibitors	Erectile dysfunction	3	2.7–2.9
Proton pump inhibitors	Acute erosive esophagitis	5	13–26
Proton pump inhibitors	Gastroesophageal reflux	5	8–14
Proton pump inhibitors	Zollinger-Ellison Syndrome	5	29–38
Histamine H-2 receptor antagonists	Acute erosive esophagitis	4	5–11
Histamine H-2 receptor antagonists	Gastroesophageal reflux	4	3–7
B-blockers, topical	Glaucoma	3	16–19
Statins	Hyperlipidemia	6	3–5
Diuretics	Hypertension, systemic arterial	5	7.7–9.4
ACE inhibitors	Hypertension, systemic arterial	9	6.5–9.1
B-blockers, oral	Hypertension, systemic arterial	7	6.3–9.1
Hypnotics	Insomnia	7	1.2–8.8
Ranibizumab, combined eye model	Neovascular age-related macular degeneration, current study	1	16.3
Bisphosphonates	Osteoporosis	3	0.8–1.1
α1-adrenergic blockers	Prostatic hyperplasia	3	0.6–1.4

All values are from the Center for Value-Based Medicine Pharmaceutical Value Index database©

SSRI selective serotonin reuptake inhibitor, statins HMG-CoA reductase inhibitors